Evidence map›Paper›PMID 28974127›Full record

Trial reportJournal of attention disorders2019

A Signature of Attention-Elicited Electrocortical Activity Distinguishes Response From Non-Response to the Non-Stimulant Atomoxetine in Children and Adolescents With ADHD.

Kristi R Griffiths, Barbora G Jurigova, John E Leikauf, Donna Palmer, Simon D Clarke, Tracey W Tsang, Erdahl T Teber, Michael R Kohn, Leanne M Williams

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of attention disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Toward Precision Medicine in ADHD.Frontiers in behavioral neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Kristi R Griffiths1 Brain Dynamics Centre, The Westmead Institue for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
Barbora G Jurigova1 Brain Dynamics Centre, The Westmead Institue for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
John E Leikauf2 Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.
Donna Palmer3 Brain Resource, Sydney, New South Wales, Australia.
Simon D Clarke1 Brain Dynamics Centre, The Westmead Institue for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
Tracey W Tsang1 Brain Dynamics Centre, The Westmead Institue for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
Erdahl T Teber7 Children's Medical Research Institute, Westmead, New South Wales, Australia.
Michael R Kohn1 Brain Dynamics Centre, The Westmead Institue for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
Leanne M Williams2 Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.
Westmead Institute for Medical Research · AUChildren's Medical Research Institute · AUPalo Alto University · USStanford University · USThe University of Sydney · AUWestmead Hospital · AUWestmead Institute · AU

Funding

TRAINING FOR CHILD PSYCHIATRY AND CHILD DEVELOPMENTT32MH019908 · NIMH · STANFORD UNIVERSITY · PI IAN H GOTLIB, DAVID S HONG · 1993 to 2026
$6.3M
NIMH NIH HHS L40 MH111091NIMH NIH HHS T32 MH019908
6 · The paper itself

Abstract

objectiveAtomoxetine has several characteristics that make it an attractive alternative to stimulants for treating ADHD, but there are currently no tests identifying individuals for whom the medication should be a first-line option.

methodWithin the ADHD Controlled Trial Investigation Of a Non-stimulant (ACTION) study, we examined neuro-cortical activity in 52 youth with ADHD. Baseline event-related potentials (ERP) were compared between those who subsequently responded to 6 weeks of atomoxetine versus those who did not.

resultsResponders were distinguished by significantly lower auditory oddball N2 amplitudes than both non-responders and typically developing controls, particularly in the right frontocentral region ( p = .002, Cohen's d = 1.1). Leave-one-out cross validation determined that N2 amplitude in this region was able to accurately predict non-responders with a specificity of 80.8%. There were no P3 differences between responders and non-responders.

conclusionThe N2 amplitude is a biomarker that may have utility in predicting response to atomoxetine for youth with ADHD.

Indexed as

Adrenergic Uptake InhibitorsAtomoxetine HydrochlorideAttentionAttention Deficit Disorder with HyperactivityEvoked PotentialsAdolescentBiomarkersBrain MappingCentral Nervous System StimulantsChildCross-Over StudiesDouble-Blind MethodElectroencephalographyFemaleHumansMaleAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideBiomarkersCentral Nervous System StimulantsADHDatomoxetineevent-related potentialsN200P300

Identifiers

PMID28974127
PMCPMC8215986
OpenAlexW2761385265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.